Our hepatitis B surface antibody (anti-HBs) assay has recently been replaced (at short notice, by the manufacturer – Abbott) by a new improved version of the assay that has been standardised against new WHO international standards.
The average antibody titres obtained by this new version of the assay are higher than that of the previous version, and are expected to be more in keeping with results produced by anti-HBs assays of other leading manufacturers (including Roche), on the basis of past NEQAS data as well as findings from a recent inhouse evaluation, and we are therefore confident that this change represents a quality improvement.
The conversion will take effect on the 3rd of February 2016.
For further advice or to discuss patient results please contact the Medical Virology team on extension 10134, or email Dr David Muir, Consultant Virologist (email@example.com).
To view communication sent to our users see here